Neonatal vaccination refers to the administration of vaccines to infants within the first month of life, aiming to provide early protection against infectious diseases. While some vaccines are given shortly after birth, others are scheduled in subsequent weeks, following a carefully designed immunization schedule. Common neonatal vaccines include those targeting hepatitis B, which is often administered shortly after birth to prevent perinatal transmission. Additionally, vaccines against tuberculosis, polio, and other diseases are typically initiated in the first few weeks of life. Neonatal vaccination is crucial as it establishes early immunity in infants who are particularly vulnerable to severe infections. It also contributes to the concept of "herd immunity," helping protect those who are unable to receive vaccinations due to medical reasons. Ensuring high vaccination coverage in neonates is a public health priority, as it prevents the spread of infectious diseases and minimizes the risk of outbreaks. Neonatal vaccination programs are continuously updated to incorporate new vaccines and enhance protection against a broader range of pathogens, contributing to improved global child health.
Khursheed Nadeem Anwer
IMUNON, United States
Ping Xie
Rutgers University, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Ahmed Abdulazeez
BHRUT Trust, United KingdomSubmit your abstract Today
Title : A promising novel approach to DNA vaccines
Khursheed Nadeem Anwer, IMUNON, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : The importance of post-marketing surveillance and real-world data for a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Advances in vaccines: Revolutionizing disease prevention
Delia Teresa Sponza, Dokuz Eylul University, Turkey